DXB gets $6M R&D Tax Incentive Rebate

We’re very pleased to see our late stage biotech Investment Dimerix (ASX:DXB), got a sizeable R&D Tax Incentive Rebate from the Australian Government today.

A total of $6M, in fact.

The large rebate puts DXB in a more robust financial position going into the interim analysis point for its Phase 3 FSGS trial - our main bet for DXB.

DXB spent a significant amount last quarter (~$7.2M) setting up the trial sites for its FSGS trial - and that big outlay is now largely paid for.

Like many biotechs, DXB has tracked the broader sector down the charts and currently sits 17.5 cents close to our initial entry price of 20 cents.

We remain Invested to see the results of the FSGS trial, in particular the interim analysis point which DXB remains on track for in mid-2023.

This looms as a major catalyst for DXB, especially in light of some of the major transactions happening in the market for kidney diseases.

What’s next for DXB? We’re looking for a further update regarding patient recruitment for the FSGS trial.